Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
Abstract
:1. Introduction
- Does switching from adalimumab originator (ADAO) to biosimilar ABP 501 in HS patients have an influence on disease course?
- What is the rate of non-response among patients with HS who were switched to biosimilar ABP 501?
- Does disease severity have an impact on the response rate to ABP 501?
- Do comorbidities affect the response to biosimilar ABP 501 in patients with HS?
2. Methods
2.1. Study Center and Data Collection
- Treatment starts with ADAO after inclusion in the registry;
- Treatment with ADAO between January 2021 and August 2021;
- Treatment duration with ADAO of at least 24 weeks;
- Hidradenitis Suppurativa Clinical Response (HiSCR) achievement prior to switching, defined as 50% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline [14].
2.2. Study Setting
2.3. Statistical Analysis
2.4. Ethics
3. Results
3.1. Demographic and Patient Characteristics
3.2. Descriptive Analysis of the Population with AE or LoR vs. the Non-AE/Non-LoR Population
3.3. Correlation Analysis between Variables and LoR
3.4. Statistical Analysis
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zouboulis, C.C.; del Marmol, V.; Mrowietz, U.; Prens, E.; Tzellos, T.; Jemec, G.B.E. Hidradenitis suppurativa/acne inversa: Criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 2015, 231, 184–190. [Google Scholar] [CrossRef] [PubMed]
- Jemec, G.B. Clinical practice. Hidradenitis suppurativa. N. Engl. J. Med. 2012, 366, 158–164. [Google Scholar] [CrossRef] [PubMed]
- Alikhan, A.; Lynch, P.J.; Eisen, D.B. Hidradenitis suppurativa: A comprehensive review. J. Am. Acad. Dermatol. 2009, 60, 539–561. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C.; Bechara, F.G.; Dickinson-Blok, J.L.; Gulliver, W.; Horváth, B.; Hughes, R.; Kimball, A.B.; Kirby, B.; Martorell, A.; Podda, M.; et al. Hidradenitis suppurativa/acne inversa: A practical framework for treatment optimization—Systematic review and recommendations from the HS ALLIANCE working group. J. Eur. Acad. Dermatol. Venereol. 2019, 33, 19–31. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. Expert Rev. Clin. Immunol. 2016, 12, 1015–1026. [Google Scholar] [CrossRef] [PubMed]
- Jang, D.-I.; Lee, A.-H.; Shin, H.-Y.; Song, H.-R.; Park, J.-H.; Kang, T.-B.; Lee, S.-R.; Yang, S.-H. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int. J. Mol. Sci. 2021, 22, 2719. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C.; Okun, M.M.; Prens, E.P.; Gniadecki, R.; Foley, P.A.; Lynde, C.; Weisman, J.; Gu, Y.; Williams, D.A.; Jemec, G.B. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J. Am. Acad. Dermatol. 2019, 80, 60–69. [Google Scholar] [CrossRef] [PubMed]
- Marzano, A.V.; Genovese, G.; Casazza, G.; Moltrasio, C.; Dapavo, P.; Micali, G.; Sirna, R.; Gisondi, P.; Patrizi, A.; Dini, V.; et al. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: A retrospective, real-life multicentre cohort study. Br. J. Dermatol. 2021, 184, 133–140. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C.; Gulliver, W.; Ingram, J.; Kirby, B.; Giamarellos-Bourboulis, E.J.; Podda, M.; Tzellos, T.; Jemec, G.B.E. Endpoints of clinical trials for hidradenitis suppurativa: Proceedings of a round-table session. Exp. Dermatol. 2020, 29 (Suppl. 1), 67–72. [Google Scholar] [CrossRef] [PubMed]
- Constantin, M.M.; Cristea, C.M.; Taranu, T.; Bucur, S.; Constantin, T.; Dinu, A.; Jinga, M.; Nita, I.E. Biosimilars in dermatology: The wind of change. Exp. Ther. Med. 2019, 18, 911–915. [Google Scholar] [PubMed]
- European Medicines Agency. Guideline on Similar Biological Medicinal Products. 2014. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf (accessed on 5 January 2022).
- Kanase, S.J.; Gavhane, Y.N.; Khandekar, A.; Gurav, A.S.; Yadav, A.V. Biosomilar: An overview. Int. J. Pharm. Sci. Res. 2013, 4, 2132–2144. [Google Scholar]
- Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 2002, 1, 457–462. [Google Scholar] [CrossRef] [PubMed]
- Kimball, A.; Sobell, J.; Zouboulis, C.; Gu, Y.; A Williams, D.; Sundaram, M.; Teixeira, H.; Jemec, G. HiSCR (Hidradenitis Suppurativa Clinical Response): A novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 989–994. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C.; Tzellos, T.; Kyrgidis, A.; Jemec GB, E.; Bechara, F.G.; Giamarellos-Bourboulis, E.J. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br. J. Dermatol. 2017, 177, 1401–1409. [Google Scholar] [CrossRef] [PubMed]
- Hurley, H.J. Hidradenitis suppurativa. In Roenigk & Roenigk’s Dermatologic Surgery: Principles and Practice, 2nd ed.; Roenigk, R.K., Roenigk, H.H., Jr., Eds.; Marcel Dekker, Inc.: New York, NY, USA, 1996; pp. 623–645. [Google Scholar]
- Montero-Vilchez, T.; Cuenca-Barrales, C.; Rodriguez-Tejero, A.; Martinez-Lopez, A.; Arias-Santiago, S.; Molina-Leyva, A. Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa. J. Clin. Med. 2022, 11, 1007. [Google Scholar] [CrossRef] [PubMed]
- Ricceri, F.; Rosi, E.; Di Cesare, A.; Pescitelli, L.; Fastame, M.T.; Prignano, F. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa. Dermatol. Ther. 2020, 33, e14387. [Google Scholar] [CrossRef] [PubMed]
- Cohen, S.; Genovese, M.C.; Choy, E.; Perez-Ruiz, F.; Matsumoto, A.; Pavelka, K.; Pablos, J.L.; Rizzo, W.; Hrycaj, P.; Zhang, N.; et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann. Rheum. Dis. 2017, 76, 1679–1687. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C. First real-world data provides evidence for a “window of opportunity” in hidradenitis suppurativa/acne inversa treatment. Br. J. Dermatol. 2021, 184, 10–11. [Google Scholar] [CrossRef] [PubMed]
Total Population (n = 94) | No Loss of Response (n = 63) | Loss of Response ± AE * (n = 31) | Differences between Groups | ||||
---|---|---|---|---|---|---|---|
Variable | Mean | SD | Mean | SD | Mean | SD | p-value & Cohen’s d |
Gender (1 = m; 0 = f) | 0.49 | 0.50 | 0.52 | 0.50 | 0.42 | 0.50 | 0.385 |
Age | 39.27 | 13.23 | 38.40 | 13.44 | 41.03 | 12.81 | 0.333 |
Hurley score (t0) | 2.26 | 0.67 | 2.33 | 0.65 | 2.10 | 0.70 | 0.125 |
IHS4 (t0) | 10.90 | 7.98 | 10.94 | 8.24 | 10.84 | 7.56 | 0.056 |
IHS4 (t1) | 5.22 | 8.60 | 6.62 | 8.95 | 2.39 | 7.16 | 0.032, d = 0.47 |
IHS4 (t2) | 5.57 | 8.80 | 5.14 | 9.06 | 6.45 | 8.31 | 0.007, d = 0.54 |
Number of comorbidities | 2.19 | 1.89 | 2.27 | 1.91 | 2.03 | 1.87 | 0.553 |
Number of nodules (t0) | 3.01 | 3.48 | 2.65 | 3.49 | 3.74 | 3.39 | 0.024, d = 0.23 |
Number of nodules (t1) | 0.72 | 1.35 | 0.79 | 1.53 | 0.58 | 0.89 | 0.863 |
Number of nodules (t2) | 0.99 | 1.94 | 0,56 | 1.53 | 1.87 | 2.38 | <0.000, d = 0.43 |
Number of tunnels (t0) | 1.83 | 1.88 | 1.94 | 1.98 | 1.61 | 1.65 | 0.605 |
Number of tunnels (t1) | 1.12 | 2.06 | 1.43 | 2.12 | 0.48 | 1.81 | 0.001, d = 0.35 |
Number of tunnels (t2) | 1.12 | 2.02 | 1.13 | 2.08 | 1.10 | 1.94 | 0.630 |
Number of abscesses (t0) | 0.23 | 0.73 | 0.27 | 0.83 | 0.16 | 0.45 | 0.809 |
Number of abscesses (t1) | 0.03 | 0.18 | 0.05 | 0.22 | 0.00 | 0.00 | 0.219 |
Number of abscesses (t2) | 0.07 | 0.30 | 0.03 | 0.18 | 0.16 | 0.45 | 0.064 |
Variable | Differences at t1 and t2 (p-Value) | Correlation between Variable and Loss of Efficacy (p-Value) |
---|---|---|
Age | - | 0.367 |
ADAO in month | - | 0.448 |
Sex | - | 0.341 |
Hurley | - | 0.262 |
IHS4 | 0.000 1, 0.026 2 | 0.237 |
Number of nodules | 0.019 1, 0.486 2 | 0.474 |
Number of tunnels | 0.000 1, 0.109 2 | 0.036 |
Number of abscesses | 0.125 1, 1.000 2 | 0.221 |
Number of comorbidities | - | 0.570 |
Number of pre-existing conditions | - | 0.089 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kirsten, N.; Ohm, F.; Gehrdau, K.; Girbig, G.; Stephan, B.; Ben-Anaya, N.; Pinter, A.; Bechara, F.G.; Presser, D.; Zouboulis, C.C.; et al. Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest. Life 2022, 12, 1518. https://0-doi-org.brum.beds.ac.uk/10.3390/life12101518
Kirsten N, Ohm F, Gehrdau K, Girbig G, Stephan B, Ben-Anaya N, Pinter A, Bechara FG, Presser D, Zouboulis CC, et al. Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest. Life. 2022; 12(10):1518. https://0-doi-org.brum.beds.ac.uk/10.3390/life12101518
Chicago/Turabian StyleKirsten, Natalia, Frenz Ohm, Kathrin Gehrdau, Gefion Girbig, Brigitte Stephan, Nesrine Ben-Anaya, Andreas Pinter, Falk G. Bechara, Dagmar Presser, Christos C. Zouboulis, and et al. 2022. "Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest" Life 12, no. 10: 1518. https://0-doi-org.brum.beds.ac.uk/10.3390/life12101518